China’s mAb and ADC Licensing Surged to Triple That of the U.S. in 2024—Will Trade Tensions Impact Growth?
The Surge of Oncology Licensing Deals in China’s Biopharmaceutical Sector In an exciting development, the biopharmaceutical landscape in China has witnessed an unprecedented surge in oncology drug licensing deals in 2024. Notably, the total deal … Read more